SHANGHAI, China, Oct. 18 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that it has been nominated the winner of Deloitte Technology Fast 50 China 2007, a ranking of the fastest growing technology companies in China as recognized by Deloitte Touche Tohmatsu (Deloitte).
The Deloitte Technology Fast 50 China program is an annual award program that ranks technology, media, and telecommunications companies located in Mainland China and Hong Kong. According to Deloitte, winners are selected based on their average revenue growth rates over the last three years. WuXi PharmaTech has been included on such a high-profile list for three consecutive years since Deloitte China launched this award program in 2005. Participants in the Deloitte Technology Fast 50 China program will automatically qualify for participation in the Deloitte Technology Fast 500 Asia Pacific 2007 program, which annually recognizes the 500 fastest growing technology companies in Asia Pacific. This will be the fourth consecutive year that WuXi PharmaTech wins such a prestigious award.
"We're honored to receive such a distinguished award once again in recognition of our ongoing success," commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "The award reflects our consistent high operation standards and transparency, and tireless dedication to customer satisfaction. In 2007 we continued to expand service offering capabilities and capacities to offer more value-added and responsive services to our collaborative partners."
About WuXi PharmaTech
Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, toxicology, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com .
For more information, please contact:
|SOURCE WuXi PharmaTech|
Copyright©2007 PR Newswire.
All rights reserved